Fortune HealthCare, India

The Indian pharmaceutical market, after experiencing healthy growth in the last few decades, is currently at the apex of transformation. The growth generated by foreign pharmaceutical companies, which entered the Indian market without any apprehension after the introduction of the “Product Patent” regime in 2005, led India to a new level of becoming a more integrated market with global pharmaceutical companies, with Fortune HealthCare being one of the most prominent of them.

Fortune HealthCare is headquartered in Baroda, Gujarat (India), with Mr. Mittal Patel at the wheel of the company as its CEO since its foundation in 2004. The company operates both on the level of research and manufacture as well as global supply and exporting.

Generics by Fortune HealthCare

The Indian pharmaceutical market is predominantly a generic market as it represents 20% of global exports of generic medicines (in terms of volume). The industry it depends heavily on imports from countries like China for its supply of active substances. The market is an attractive destination for global pharmaceutical companies due to its rich knowledge base and cost-effective manufacturing and research practice. Rapid growth in the generics sector has been the main driver in the last decade, and the biggest part of the country's generic medicine production served the public health system.

Active substances or generics, are active raw materials that provide therapeutic effect to the medicine. Generics are the largest market segment of the Indian pharmacy.

India is the third largest active ingredients market in the Asia-Pacific region, and China is the main competitor. India exports raw materials to regulated and semi-regulated markets.

Fortune HealthCare is a typical representative of the Indian pharmaceutical market, with its main focus centered on the production of generic medications. The company made heavy investments into the steps that promote the low cost for innovative medicines, such as the adoption of new technologies or the use of compounds of High Potency Active Ingredients (HPAPI) for effective targeted therapies, thus causing a positive impact on the overall growth of the market of generics.

Fortune HealthCare has been steadily increasing the investments and focus on taking advantage of opportunities in the growing market for generics from the United States, being a part of the Indian generics sector that reached US$71.9 billion by 2018. Fortune HealthCare has the advantage of having large facilities which allows it to enter into lines of producing more sophisticated products, such as analgesics, SSRIs, sexual dysfunction drugs, anti-allergy medications, ulcer medications and other advanced products.

Medications produced at Fortune HealthCare have a bigger purpose than simply providing therapeutic relief; the company’s vision is to continue developing and producing affordably priced solutions for people around the world whose health insurance is either insufficient or non-existent. It is the firm belief in the equality of human rights when it comes down to access to healthcare that Fortune HealthCare keeps on driving the company towards its ambitious goals.

Today, high-quality products by Fortune HealthCare are popular in different corners of the world and can be purchased online at a fraction of the price charged for their original analogs.